Stenocare
Stenocare is a Danish pharmaceutical company that develops, imports, and distributes prescription-based medical cannabis oils and flower products to patients across seven countries, leveraging patented ASTRUM lymphatic targeting technology with 2.6x improved bioavailability.
- Company typePublic
- Founded2017
- HeadquartersAllerød, Denmark
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Stenocare does
Stenocare A/S is a Danish pharmaceutical company founded in 2017 and listed on Nasdaq First North Denmark (ticker: STENO), headquartered in Copenhagen. The company innovates, imports, and distributes prescription-based medical cannabis products — THC oils, CBD oils, THC/CBD combination oils, the high-concentration CBD100 formulation, and, following the November 2025 CannGros acquisition, five flower products. Its flagship ASTRUM 10-10 oil is built on a patented Lymphatic Targeting Technology (LTT) that Stenocare holds worldwide exclusivity to apply in cannabis products; pharmacokinetic studies show 2.6x higher blood uptake and faster time-to-maximum concentration (1 hour vs 2–4 hours) compared with conventional MCT-oil products.
Stenocare sells exclusively through prescription-based pharmacy distribution across seven markets: Denmark, Sweden, Norway, Germany, the UK, Australia, and France (entered 2026 via ICMF and Movianto partnerships). Channel partners include Apotek 1 in Norway, ADREXPharma in Germany, Cannvalate in Australia, and WEECO Pharma (co-branded Germany launch). The company transitioned under its STENOCARE 3.0 strategy from a cultivation-inclusive model to an asset-light innovation and trading company, focusing capital on product development and international expansion.
Revenue is generated through unit sales of approved products to pharmacies and distributors; pricing is not publicly disclosed, though Denmark provides partial reimbursement (up to DKK 20,000 annually). FY2025 net sales reached a record DKK 7.0 million (~107% YoY growth in Q4 2025), with CannGros expected to add DKK 4–6 million in annual revenue from 2026. The company achieved three consecutive quarters of positive EBITDA in 2025 and is targeting full-year profitability in 2026.
Stenocare firmographics
Firmographics- Name
- Stenocare
- Legal name
- Stenocare A/S
- Website
- https://stenocare.com
- Company type
- Public
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Stenocare is a Danish pharmaceutical company that develops, imports, and distributes prescription-based medical cannabis oils and flower products to patients across seven countries, leveraging patented ASTRUM lymphatic targeting technology with 2.6x improved bioavailability.
- Ownership category
- akta.pro rank
Stenocare industry classification
Industry- Product category
- Medical Cannabis Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411), Drugs and Druggists' Sundries Merchant Wholesalers (42421)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services) (CRANAFAI)
Keywords
Where Stenocare is headquartered
LocationHeadquarters
- HQ city
- Allerød
- HQ country
- Denmark
- HQ region
- Europe
Offices1 record
Markets served
Stenocare business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Medical Cannabis Product Sales: Stenocare generates revenue from the sale of prescription-based medical cannabis oil products (THC, CBD, and combined formulations) and flower products through pharmacies in Denmark, Sweden, Norway, Germany, UK, Australia, and France. Revenue is generated through product sales to pharmacies and distributors.
- International Market Expansion: Revenue growth driven by geographic expansion into new markets (Germany, Australia, Norway, France) with approved products, leveraging existing product portfolio and new product launches like ASTRUM.
Go-to-market motion2 records
Distribution channels5 records
Marketing channels5 records
Stenocare product offering
Product offeringCore offering
Stenocare is a Danish pharmaceutical company that innovates, imports, and distributes prescription-based medical cannabis oil and flower products across Denmark, Sweden, Norway, Germany, the UK, and Australia. The company manufactures and markets THC, CBD, THC/CBD combination, and high-concentration CBD100 oil formulations under the Danish Pilot Programme, plus the proprietary ASTRUM 10-10 product built on patented lymphatic targeting technology with 2.6x improved bioavailability. Following the November 2025 acquisition of CannGros ApS, the portfolio expanded to nine approved products including five flower-based medical cannabis products.
Product overview
Stenocare is a Danish pharmaceutical company that innovates, imports, and distributes prescription-based medical cannabis products. The company operates across Denmark, Sweden, Norway, Germany, UK, and Australia with a portfolio of nine approved products spanning medical cannabis oils and flower products. The core product line includes THC Oil Stenocare (30 mg/mL THC), CBD Oil Stenocare (20 mg/mL CBD), THC/CBD Oil Stenocare (15/24 mg/mL), and CBD100 Oil Stenocare (100 mg/mL CBD) — all approved under Denmark's permanent medical cannabis framework. The company also offers the patented ASTRUM 10-10 Oil product line featuring lymphatic targeting technology that demonstrates 2.6x improved bioavailability compared to traditional MCT-oil formulations, approved in Germany, Australia, and Norway. Following the November 2025 acquisition of CannGros ApS, Stenocare expanded into five flower-based products alongside its oil portfolio. Products are distributed through pharmacies via prescription and are regulated by respective national health authorities including the Danish Medicines Agency, German BfArM, and Australian TGA.
Differentiator
Problem solved
Functional benefit
Brands
- ASTRUM: Innovative and patented next-generation medical cannabis oil product featuring advanced oil technology designed to enhance cannabinoid bioavailability. Products include ASTRUM 10-10 (10mg/ml THC and 10mg/ml CBD in 30ml bottle).
- STENOCARE 3.0
Products and services
- THC Oil Stenocare Prescription-based medical cannabis oil containing 30 mg/mL THC in a 30 mL bottle with oral dosing syringe; approved under the Danish Pilot Programme and listed on the Danish Medicines Agency's list of cannabis products for medical use.
- CBD Oil Stenocare Prescription-based medical cannabis oil containing 20 mg/mL CBD, approved under the Danish Pilot Programme for treatment of various conditions.
- THC/CBD Oil Stenocare Combination THC/CBD medical cannabis oil containing 15 mg/mL THC and 24 mg/mL CBD, approved under the Danish Pilot Programme; Stenocare is the first and only supplier of this product in Denmark.
- CBD100 Oil Stenocare High-concentration CBD medical cannabis oil containing 100 mg/mL CBD and 5 mg/mL THC, approved December 2024; Stenocare is the only supplier under the Danish Pilot Programme to offer this high-strength CBD oil.
- ASTRUM 10-10 Oil Next-generation patented medical cannabis oil using lymphatic targeting technology (LTT-oil) with 10 mg/mL THC and 10 mg/mL CBD in a 30 mL bottle; demonstrates 2.6x higher blood uptake and 1-hour time to maximum concentration compared to traditional MCT-oil products; approved in Australia, Germany, and Norway.
- CannGros Flower Products Five approved medical cannabis flower products acquired from DanCann Pharma through the November 2025 share exchange, expanding Stenocare's portfolio from oils into flower-based medical cannabis products for the Danish market.
- Balanced 12.5-12.5 Oil (Australia) Medical cannabis oil containing 12.5 mg/mL THC and 12.5 mg/mL CBD, Stenocare's initial product for the Australian market, launched Q4 2022.
- AD 10-10 STENOCARE Extrakt (Germany) Medical cannabis oil product containing 10 mg/mL THC and 10 mg/mL CBD, approved in Germany through the ADREXPharma partnership and eligible for statutory insurance reimbursement.
Quantifiable outcome
- 2.6x higher blood uptake of cannabinoids compared to traditional MCT-oil products
- +3 more outcomes
Companies that use Stenocare
Customer profileSegments3 records
Ideal customer profiles3 records
Stenocare technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Stenocare partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core.
- ICMF (Institut des Cannabinoïdes Médicaux Français)coreStrategic partnership for French market entry. ICMF assists with regulatory dossier submission for ASTRUM 10-10 medical cannabis oil product to French National Health Authority (HAS) for reimbursement evaluation. France is transitioning its four-year pilot program into a permanent framework in 2026.
- Movianto (Yusen Logistics Healthcare)corePartnership with France's leading pharmaceutical distributor for nationwide logistics and pharmacy distribution. Movianto handles nationwide distribution of Stenocare products to pharmacies under the partnership.
- WEECO Pharma GmbHcoreStrategic partnership to launch premium medical cannabis oils in Germany. First product 'WEECO ASTRUM 10-10 extract' (10mg/ml THC and 10mg/ml CBD in 30ml bottle) scheduled for February 2026 launch. Leverages WEECO's regulatory expertise and established distribution network.
- DanCann Pharma A/ScoreAcquisition of CannGros ApS from DanCann Pharma through share exchange (5 million new Stenocare shares issued). Expands product portfolio into flower-based medical cannabis. DanCann now owns 11.5% of Stenocare following the transaction.
- ADREXPharmacoreGerman pharmaceutical partner for market entry and regulatory collaboration with BfArM (Federal Institute for Drugs and Medical Devices). Product 'AD 10-10 STENOCARE Extrakt' approved and launched October 2023.
- Apotek 1coreNorwegian pharmacy chain and leading distributor partnership. Distribution agreement for medical cannabis oil products in Norway including THC Drops 30mg/mL, CBD Drops 20mg/mL, and Balanced products.
- CannvalatecoreAustralian medical cannabis company partnership for market entry. Provides access to 600+ pharmacies and 3,000 doctors through online clinic platform. Product launched Q4 2022 with Balanced 12.5-12.5 oil product.
Scale indicators8 records
Recent moves11 records
Expansion highlights6 records
Stenocare competitors and assessment
Company assessmentEmerging players
- Senza Capital (now part of Kanabo Group): European medical cannabis distributor focused on pharmacy-channel sales across multiple EU markets. Comparable as a smaller-scale European medical cannabis platform.
- Cannvalate Pty Ltd: Australian medical cannabis distributor providing access to 600+ pharmacies and 3,000 doctors and Stenocare's Australian distribution partner. Comparable in market role (medical cannabis distribution), though Australia-focused.
- Mamedica: UK medical cannabis clinic and distributor prescribing THC/CBD products to patients via specialist doctors. Comparable in European prescription cannabis model, though with a clinic-led rather than product-led approach.
Direct peers
- Cantourage Group SE: Berlin-based medical cannabis distributor operating in Germany and other European markets. Closely comparable as a European-focused prescription cannabis oils platform leveraging partner producers and proprietary distribution.
- DanCann Pharma A/S: Danish medical cannabis company that previously owned CannGros ApS and now holds ~11.5% of Stenocare. Directly comparable as a Denmark-based player importing and distributing prescription medical cannabis oils and flowers.
- Demecan GmbH: German vertically integrated medical cannabis producer and distributor supplying pharmacies in Germany. Comparable as a European prescription medical cannabis operator with regulatory approvals and pharmacy-channel distribution.
Broad incumbents
- Aurora Cannabis Inc. Large Canadian cannabis producer with established European medical cannabis operations. Comparable as a broad multi-jurisdiction medical cannabis supplier, though at significantly larger scale and with a much broader product portfolio.
- Tilray Brands Inc. Global cannabis incumbent with significant medical cannabis operations across Europe, including Germany. Comparable in target market (prescription medical cannabis in Europe) and pharmacy-channel distribution, but at vastly greater scale.
- Orifarm Group: Large Danish/European pharmaceutical company with parallel/specialty pharma distribution and product development capabilities. Comparable as a Northern European pharma operator with broad portfolio and regulatory expertise (board member Søren Melsing Frederiksen is VP at Orifarm).
- Jazz Pharmaceuticals plc (GW Pharmaceuticals): Owner of GW Pharma's Epidiolex and broader cannabinoid-derived prescription drug portfolio. Comparable as a prescription cannabinoid pharmaceutical business targeting European and global markets, though at much larger scale with FDA-approved products.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights6 records
Customer concentration
Stenocare social profiles
Digital presenceStenocare financial estimates
Financial estimateRevenue estimate
Valuation estimate
Stenocare leadership team
Management profileNumber of profiles
Profiles7 records
Stenocare subsidiaries and ownership
Company hierarchySubsidiaries1 record
Stenocare funding detail
Funding detailFunding overview
Funding rounds2 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Stenocare M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Stenocare
What does Stenocare do?
Stenocare is a Danish pharmaceutical company that innovates, imports, and distributes prescription-based medical cannabis oil and flower products across Denmark, Sweden, Norway, Germany, the UK, and Australia. The company manufactures and markets THC, CBD, THC/CBD combination, and high-concentration CBD100 oil formulations under the Danish Pilot Programme, plus the proprietary ASTRUM 10-10 product built on patented lymphatic targeting technology with 2.6x improved bioavailability. Following the November 2025 acquisition of CannGros ApS, the portfolio expanded to nine approved products including five flower-based medical cannabis products.
Is Stenocare a public or private company?
Stenocare is a public company. It is classified as public and is currently operating.
When was Stenocare founded?
Stenocare was founded in 2017. It employs 1 to 10 people.
Where is Stenocare based?
Stenocare is headquartered in Allerød, Denmark, in the Europe region.
How does Stenocare make money?
Two revenue lines are on record. Medical Cannabis Product Sales are the primary driver. The others are international Market Expansion.
Who are Stenocare's main competitors?
Emerging players on record are Senza Capital (now part of Kanabo Group), Cannvalate Pty Ltd and Mamedica. Direct peers are Cantourage Group SE, DanCann Pharma A/S and Demecan GmbH. Broad incumbents are Aurora Cannabis Inc., Tilray Brands Inc., Orifarm Group and Jazz Pharmaceuticals plc (GW Pharmaceuticals).
Does Stenocare have an API?
No public API is recorded for Stenocare.
What industry is Stenocare in?
Stenocare's product category is Medical Cannabis Pharmaceuticals. Its primary akta.pro industry code is CRANAFAI, Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services). Its NAICS code is 325412 and its SIC code is 2834.